type 2 diabetes
Conditions
Interventions
nasal GLP-1(recombinant)
placebo
Sponsors
University of Miyazaki Faculty of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. type 2 diabetes in accordance with WHO criteria who are treated with oral anti-diabetic agents 2. HbA1c 6.5~9.0% 3. age between 20 and 70 years old 4. out-clinic patient 5. informed consent
Exclusion criteria
Exclusion criteria: 1. type 1 diabetes 2. brittle diabetes 3. patients who need insulin therapy 4. problems in nasal cavity 5. bronchial asthma 6. preproliferative and proliferative diabetic retinopathy 7. chronic renal failure(serum CRE>3.0mg/dl) and who are treated with hemodialysis 8. acute myocardial infarction, unstable angina, acute coronary syndrome 9. obstruction of gastrointestinal tract 10. tube feeding or intravenous hyperalimentation 11. neoplasm 12. severe liver injury 13. chronic alcoholism or drug abuse 14. drug allergy 15. pregnant or in the lactation period 16. capability of pregnancy 17. history of other clinical trials within 2 months prior to the informed consent 18. patients whom the physician judges to be ineligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| glycoalbumin 1,5-AG amount of meal | — |
Secondary
| Measure | Time frame |
|---|---|
| plasma glucose insulin concentration glucagon concentration lipid profile body weight and body composition level of hunger appetite score | — |
Countries
Japan
Contacts
Public ContactMasanari Mizuta
University of Miyazaki Faculty of Medicine The 3rd Dept of Medicine
Outcome results
None listed